ARDELYX, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ARDELYX, INC. (ARDX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $13.27 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-07
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $13.27M.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $3.75M, a 76.44% decline year-over-year.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$16.74M.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $24.01M.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $3.38M, a 331.21% increase from fiscal 2017.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $785.00K.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$32.41M.
- ARDELYX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$282.00K, a 100.39% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-03-31 | $13.27M 10-Q · filed 2019-05-07 | $17.02M derived: sum of 2 quarters · filed 2019-05-07 | $285.00K derived: sum of 3 quarters · filed 2019-05-07 | $24.29M derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$12.98M derived: sum of 2 quarters · filed 2019-03-06 | $11.02M derived: sum of 3 quarters · filed 2019-03-06 | $3.38M 10-K · filed 2019-03-06 |
| 2018-09-30 | -$16.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $7.27M derived: sum of 2 quarters · filed 2018-11-07 | -$368.00K 10-Q · filed 2018-11-07 | $15.56M derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-06-30 | $24.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $16.37M 10-Q · filed 2018-08-07 | $32.30M derived: sum of 3 quarters · filed 2019-05-07 | $28.11M derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-03-31 | -$7.64M 10-Q · filed 2019-05-07 | $8.29M derived: sum of 2 quarters · filed 2019-05-07 | $4.11M derived: sum of 3 quarters · filed 2019-05-07 | -$3.47M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $15.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $11.75M derived: sum of 2 quarters · filed 2019-03-06 | $4.17M derived: sum of 3 quarters · filed 2019-03-06 | $785.00K 10-K · filed 2019-03-06 |
| 2017-09-30 | -$4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$11.76M derived: sum of 2 quarters · filed 2018-11-07 | -$15.14M 10-Q · filed 2018-11-07 | -$100.91M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-06-30 | -$7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$10.96M 10-Q · filed 2018-08-07 | -$96.72M derived: sum of 3 quarters · filed 2019-03-06 | -$83.03M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-03-31 | -$3.38M 10-Q · filed 2018-05-08 | -$89.15M derived: sum of 2 quarters · filed 2019-03-06 | -$75.46M derived: sum of 3 quarters · filed 2019-03-06 | -$100.47M derived: sum of 4 quarters · filed 2019-03-06 |
| 2016-12-31 | -$85.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$72.07M derived: sum of 2 quarters · filed 2019-03-06 | -$97.08M derived: sum of 3 quarters · filed 2019-03-06 | -$32.41M 10-K · filed 2019-03-06 |
| 2016-09-30 | $13.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$11.32M derived: sum of 2 quarters · filed 2017-11-07 | $53.36M 10-Q · filed 2017-11-07 | $31.31M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$25.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $39.66M 10-Q · filed 2017-08-09 | $17.62M derived: sum of 3 quarters · filed 2018-03-14 | $5.13M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $64.67M 10-Q · filed 2017-05-05 | $42.63M derived: sum of 2 quarters · filed 2018-03-14 | $30.14M derived: sum of 3 quarters · filed 2018-03-14 | $73.36M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$22.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$34.53M derived: sum of 2 quarters · filed 2018-03-14 | $8.69M derived: sum of 3 quarters · filed 2018-03-14 | -$282.00K 10-K · filed 2018-03-14 |
| 2015-09-30 | -$12.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $30.73M derived: sum of 2 quarters · filed 2016-11-07 | $21.76M 10-Q · filed 2016-11-07 | $17.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $43.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $34.25M 10-Q · filed 2016-08-08 | $29.49M derived: sum of 3 quarters · filed 2017-02-17 | $23.72M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$8.97M 10-Q · filed 2016-05-09 | -$13.73M derived: sum of 2 quarters · filed 2017-02-17 | -$19.50M derived: sum of 3 quarters · filed 2017-02-17 | $65.10M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | -$4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$10.53M derived: sum of 2 quarters · filed 2017-02-17 | $74.06M derived: sum of 3 quarters · filed 2017-02-17 | $72.85M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$5.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $78.82M derived: sum of 2 quarters · filed 2015-11-12 | $77.61M 10-Q · filed 2015-11-12 | $88.52M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-06-30 | $84.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $83.38M 10-Q · filed 2015-08-12 | $94.29M derived: sum of 3 quarters · filed 2016-03-04 | $94.06M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-03-31 | -$1.21M 10-Q · filed 2015-05-12 | $9.69M derived: sum of 2 quarters · filed 2016-03-04 | $9.47M derived: sum of 3 quarters · filed 2016-03-04 | |
| 2013-12-31 | $10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | $10.69M derived: sum of 2 quarters · filed 2016-03-04 | $1.53M 10-K · filed 2016-03-04 | |
| 2013-09-30 | -$221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$9.38M 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | -$9.15M 10-Q · filed 2014-08-08 | |||
| 2012-12-31 | $22.12M 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |